Side-by-side · Research reference
HGH Fragment 176-191vsMazdutide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED28/59 cited
BPhase 3HUMAN-REVIEWED19/62 cited
HGH Fragment 176-191
GH Fragment · Pre-Clinical
SQ · IP (animal) · Oral (tested)
01Mechanism of Action
Parameter
HGH Fragment 176-191
Mazdutide
Primary target
Beta-3 adrenergic receptors on adipocytesHeffernan 2001
GLP-1 receptor and glucagon receptorAbdul 2026Elmendorf 2026
Pathway
Fragment → β3-AR upregulation → Enhanced lipolytic sensitivityHeffernan 2001
Dual agonism: GLP-1R → satiety, insulin secretion, gastric emptying delay; GCGR → hepatic lipolysis, energy expenditure, thermogenesisElmendorf 2026Abulehia 2026
Downstream effect
Increased lipolysis and beta-3 AR mRNA expression without IGF-1 axis activation
Weight loss via appetite suppression (GLP-1 axis) and increased energy expenditure (glucagon axis); improved glycemic control in T2D
Feedback intact?
N/A — does not interact with GH/IGF-1 axis
Yes — physiological receptor-mediated signaling preserved
Origin
Synthetic peptide derived from hGH residues 176-191; AOD9604 includes N-terminal tyrosine (177-191)Cox 2015
Synthetic oxyntomodulin analogue — endogenous peptide with dual GLP-1/glucagon activity
Antibody development
Not reported in available studies
—
02Dosage Protocols
Parameter
HGH Fragment 176-191
Mazdutide
Animal dose (IP)
Not specified (14-day chronic administration)Heffernan 2001
Obese mice, daily IP injection.
—
Human equivalent dose
Not established — no published human RCTs
—
Detection window
50 pg/mL LOD in urine; stable metabolite extends detectionCox 2015
WADA-banned; anti-doping testing available.
—
Oral bioavailability
Demonstrated efficacy in animal oral administrationNg 2000
Potential for oral therapeutic development.
—
Phase 2 studied dose
—
Dose escalation
—
3 mg → 6 mg → 9 mg (titration schedule in trials)
Gradual escalation to minimize GI side effects.
Duration (trials)
—
24–48 weeks
Population
—
Non-diabetic adults BMI ≥30 kg/m² or ≥27 kg/m² with comorbidities
03Metabolic / Fat Loss Evidence
Parameter
HGH Fragment 176-191
Mazdutide
Weight gain reduction
50% reduction vs control (15.8 ± 0.6 g vs 35.6 ± 0.8 g)Ng 2000
Obese Zucker rats, 19 days oral administration.
—
Body fat reduction
Significant decrease in body weight and body fat in obese mice (14 days)Heffernan 2001
—
Lipolytic activity
Increased adipose tissue lipolytic activityNg 2000
Direct measurement in treated animals.
—
Insulin sensitivity
No adverse effect — euglycemic clamp confirmedNg 2000
Contrasts with intact hGH diabetogenic effects.
—
IGF-1 impact
No elevation — fragment does not activate GH/IGF-1 axis
—
Beta-3 AR dependency
Effect abolished in β3-AR knockout miceHeffernan 2001
Confirms β3-AR as primary mechanism.
—
Human evidence
None published — pre-clinical only
—
Percentage body weight loss
—
12.4% (pooled meta-analysis, 9 mg dose)
95% CI: -16.15% to -8.68%, random-effects model.Azam 2026
Responder rate (≥10% loss)
—
Not explicitly reported in available abstracts
Visceral fat
—
Expected benefit from glucagon-mediated lipolysis (not quantified in abstracts)
Glycemic improvement
—
HbA1c reduction in T2D cohort (Phase 3 DREAMS-3)
Key publications
—
Ji et al. Med 2026 · Azam et al. Diab Obes Metab 2026 · Luo et al. Contemp Clin Trials 2026
04Side Effects & Safety
Parameter
HGH Fragment 176-191
Mazdutide
Human safety data
Not available — no published human trials
—
Metabolic profile
Six metabolites identified; CRSVEGSCG most stableCox 2015
Detection window implications for doping control.
—
Gastrointestinal symptoms
—
Nausea, vomiting, diarrhea (most common, GLP-1 effect)
Injection site reactions
—
Erythema, pruritus, local discomfort
Hypoglycemia
—
Low risk in non-diabetic cohort; monitor in T2D with insulin or sulfonylureas
Cardiovascular effects
—
Increased heart rate (glucagon effect, transient)
Pancreatitis risk
—
Theoretical (incretin class effect); monitor amylase/lipase if abdominal pain
Thyroid C-cell tumors
—
Black box warning for GLP-1 class (rodent data); human relevance unclear
Gallbladder disease
—
Cholelithiasis, cholecystitis (rapid weight loss effect)
Tolerability
—
Generally well-tolerated; GI effects diminish with dose titration
Absolute Contraindications
HGH Fragment 176-191
- ·Competitive athletes (WADA-banned)Cox 2015
Mazdutide
- ·Personal or family history of medullary thyroid carcinoma
- ·Multiple endocrine neoplasia syndrome type 2 (MEN 2)
- ·Hypersensitivity to mazdutide or excipients
- ·Pregnancy
Relative Contraindications
HGH Fragment 176-191
- ·Absence of human safety data — experimental use only
Mazdutide
- ·History of pancreatitis
- ·Severe gastroparesis or GI motility disorders
- ·Diabetic retinopathy (monitor, risk of worsening with rapid glycemic change)
- ·Renal impairment (limited data, use with caution)
05Administration Protocol
Parameter
HGH Fragment 176-191
Mazdutide
1. Route
Subcutaneous injection primary route in research context. Oral administration demonstrated efficacy in animal models at 500 mcg/kg.
Supplied as pre-filled pen or reconstituted vial (per manufacturer instructions). Inspect solution — should be clear, colorless to pale yellow. Discard if cloudy or particulate matter present.
2. Frequency
Once daily dosing used in animal studies. Timing not specified; GH-independent mechanism suggests flexibility.
Subcutaneous — abdomen preferred, also thigh or upper arm. Rotate sites weekly. Avoid areas with scarring, moles, or active inflammation.
3. Duration
Animal protocols: 14–19 days. Human duration not established — no published trials.
Once weekly, same day each week. May be taken with or without food. If dose missed, administer within 3 days; if >3 days, skip and resume next scheduled dose.
4. Storage
Lyophilized peptide storage per standard peptide protocols. Metabolite stability suggests refrigerated reconstituted solution viable.
Refrigerate 2–8 °C. Do not freeze. May be kept at room temperature (<25 °C) for up to 14 days if needed. Protect from light.
5. Detection
Detectable in urine via SPE-LC-MS at 50 pg/mL LOD. Extended detection window via stable metabolite CRSVEGSCG.Cox 2015
Use supplied needle or compatible insulin syringe (if reconstituting). Pinch skin, inject at 90° angle. Hold 5–10 seconds before withdrawing needle to prevent leakage.